{"content":"<li class=\"n-box-item date-title\" data-end=\"1571284799\" data-start=\"1571198400\" data-txt=\"Monday, December 23, 2019\">Wednesday, October 16, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3506366\" data-ts=\"1571264957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INOV\" target=\"_blank\">INOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506366-inovalonminus-3_3-amid-report-of-750000-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inovalon -3.3% amid report of 750,000-share offering</a></h4><ul>   <li>Inovalon (NASDAQ:<a href='https://seekingalpha.com/symbol/INOV' title='Inovalon Holdings, Inc.'>INOV</a>) is <font color=\"red\">3.3% lower</font> after hours following a report that a 750,000-share block is coming on offer.</li>    <li>Those shares are offered at $15.05 each, Bloomberg reports, a 1% discount to the close.</li>    <li>The seller is unknown, but more than 10 holders own at least that many shares, according to the report.</li>    <li>The offering comes via Morgan Stanley.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3506366\" data-linked=\"Inovalon -3.3% amid report of 750,000-share offering\" data-tweet=\"$INOV - Inovalon -3.3% amid report of 750,000-share offering https://seekingalpha.com/news/3506366-inovalonminus-3_3-amid-report-of-750000-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3506366-inovalonminus-3_3-amid-report-of-750000-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506362\" data-ts=\"1571262499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506362-netflix-says-competitions-ok-in-growing-streaming-pie\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix says competition&#39;s OK in a growing streaming pie</a></h4><ul>   <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is <font color=\"green\">up 8.3%</font> now in postmarket trading after its <a href=\"https://seekingalpha.com/news/3506320-netflix-plus-10_7-percent-profits-jump-amid-solid-growth\" target=\"_blank\">Q3 earnings</a> marked a bit of a rebound from <a href=\"https://seekingalpha.com/news/3478616-netflix-minus-10_8-percent-q2-subscriber-count-misses-mark\" target=\"_blank\">last quarter</a>, when subscriber counts missed heavily.</li>    <li>With the \"streaming wars\" in early days, it could be another indication that consistently new high-profile content will trump library offerings, as subscriber count (net adds of 6.77M vs. last quarter's 2.7M) was goosed by the third season of <i>Stranger Things,</i> the most-watched season of that series with 64M households watching in the first four weeks.</li>    <li>In its <a href=\"https://seekingalpha.com/article/4296890-netflix-inc-2019-q3-results-earnings-call-presentation\" target=\"_blank\">investor letter</a>, the company downplayed worries about upcoming streaming competition, saying it's been competing in streaming for a long time.</li>    <li>\"The upcoming arrival of services like Disney Plus (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>), Apple TV Plus (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>), HBO Max (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>), and Peacock (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) is increased competition, but we are all small compared to linear TV,\" it says. \"The launch of these new services will be noisy. There may be some modest headwind to our near-term growth, and we have tried to factor that into our guidance. In the long term, though, we expect we\u2019ll continue to grow nicely given the strength of our service and the large market opportunity.\"</li>    <li>\"In our view, the likely outcome from the launch of these new services will be to accelerate the shift from linear TV to on demand consumption of entertainment. Just like the evolution from broadcast TV to cable, these once-in-a-generation changes are very large and open up big, new opportunities for many players.\"</li>     <li>Starting with its Q4 report in January, it will disclose revenue and membership by region, and will only provide membership guidance for global paid memberships. U.S. vs. international margin reporting is becoming less useful internally and it will stop reporting that in January.</li>    <li>For Q4, it's forecasting $5.44B in revenue, and net streaming paid adds of 7.6M to hit 165.9M paid memberships overall.</li>    <li><a href=\"http://youtube.com/netflixir\" target=\"_blank\">Earnings interview</a> (with Guggenheim's Michael Morris) still ahead at 6 p.m. ET.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3506362\" data-linked=\"Netflix says competition&#39;s OK in a growing streaming pie\" data-tweet=\"$NFLX $DIS $AAPL - Netflix says competition&#39;s OK in a growing streaming pie https://seekingalpha.com/news/3506362-netflix-says-competitions-ok-in-growing-streaming-pie?source=tweet\" data-url=\"https://seekingalpha.com/news/3506362-netflix-says-competitions-ok-in-growing-streaming-pie\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>91&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506358\" data-ts=\"1571261876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506358-diffusion-pharma-files-for-equity-offering-shares-down-24-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diffusion Pharma files for equity offering; shares down 24% after hours</a></h4><ul><li>Diffusion Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) slumps <font color=\"red\">24%</font> after hours in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1053691/000143774919020133/dffn20191014_s1.htm\" target=\"_blank\">preliminary prospectus</a> for a public offering of stock and warrants. Prices, volumes and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506358\" data-linked=\"Diffusion Pharma files for equity offering; shares down 24% after hours\" data-tweet=\"$DFFN - Diffusion Pharma files for equity offering; shares down 24% after hours https://seekingalpha.com/news/3506358-diffusion-pharma-files-for-equity-offering-shares-down-24-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3506358-diffusion-pharma-files-for-equity-offering-shares-down-24-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506354\" data-ts=\"1571261538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506354-ibm-nflx-and-aa-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM, NFLX and AA among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a> <font color=\"green\">+14.1%</font>. <a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color=\"green\">+9.2%</font>. <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color=\"green\">+7.8%</font>. <a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> <font color=\"green\">+2.9%. </font><a href='https://seekingalpha.com/symbol/AVLR' title='Avalara, Inc.'>AVLR</a> <font color=\"green\">+2.8%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> <font color=\"red\">-4.2%. </font><a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt plc'>MNK</a> <font color=\"red\">-1.8%</font>. <a href='https://seekingalpha.com/symbol/URI' title='United Rentals, Inc.'>URI</a> <font color=\"red\">-1.4%</font>. <a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a> <font color=\"red\">-1.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506354\" data-linked=\"IBM, NFLX and AA among after hour movers\" data-tweet=\"$LLNW $NFLX $AA - IBM, NFLX and AA among after hour movers https://seekingalpha.com/news/3506354-ibm-nflx-and-aa-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506354-ibm-nflx-and-aa-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506336\" data-ts=\"1571261108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506336-bofa-merrill-lynch-sees-25-upside-in-vertex-in-after-hours-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action</a></h4><ul><li>Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) resumed with Outperform rating and $2 (94% upside) price target at Oppenheimer. Shares up <font color=\"green\">4%</font> after hours.</li><li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) resumed with Buy rating and $220 (25% upside) price target at BofA Merrill Lynch.</li><li>Regeneron Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) resumed with Neutral rating and $325 (9% upside) price target at BofAML.</li><li>Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a>) resumed with Neutral rating and $90 (7% upside) price target at BofAML.</li><li>Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) resumed with Neutral rating and $37 (2% upside) price target at BofAML.</li><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) resumed with a Buy rating and $133 (23% upside) price target at BofAML.</li><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) resumed with Neutral rating and $70 (7% upside) price target at BofAML.</li><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) resumed with Buy rating and $60 (16% upside) price target at BofAML.</li><li>BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>) resumed with Buy rating and $90 (32% upside) price target at BofAML. Shares up <font color=\"green\">1% </font>after hours.</li><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) resumed with Neutral rating and $215 (6% upside) price target at BofAML.</li><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) resumed with Underperform rating and $200 (12% downside risk) price target at BofAML. Shares down a fraction after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506336\" data-linked=\"BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action\" data-tweet=\"$MBRX $VRTX $REGN - BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action https://seekingalpha.com/news/3506336-bofa-merrill-lynch-sees-25-upside-in-vertex-in-after-hours-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3506336-bofa-merrill-lynch-sees-25-upside-in-vertex-in-after-hours-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506350\" data-ts=\"1571260811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCI\" target=\"_blank\">CCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506350-crown-castleplus-1_8-after-q3-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crown Castle +1.8% after Q3 beat</a></h4><ul>   <li>Crown Castle (NYSE:<a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp. &#40;REIT&#41;'>CCI</a>) is <font color=\"green\">up 1.8%</font> after hours following <a href=\"https://seekingalpha.com/news/3506313-crown-castle-ffo-beats-0_06-beats-revenue\" target=\"_blank\">Q3 earnings</a> where it topped expectations for revenues and FFO.</li>    <li>Site rental revenues rose 6.4% to $1.26B, and adjusted funds from operations rose 12% to $646M.</li>    <li>Organic contribution to site rental revenues was $70M with about a $6M increase in straight-lined revenues.</li>    <li>Capital expenditures were $540M ($18M in land purchases, $29M in sustaining capex, and $491M in discretionary capex along with $2M in integration). Of discretionary capex, $371M was attributable to Fiber and $120M to Towers.</li>    <li>\"During the last five years, and inclusive of the <a href=\"https://seekingalpha.com/news/3506310-crown-castle-declares-1_20-dividend\" target=\"_blank\">dividend increase</a> we are announcing today, we have increased our dividend by a compounded annual growth rate of approximately 8%,\" CFO Dan Schlanger says.</li>    <li>\"Looking forward, we believe we are in a great position to deliver on our annual dividend growth target of 7% to 8% while at the same time making significant investments in our business that we believe will generate attractive long-term returns and support future growth.\"</li>    <li><a href=\"http://investor.crowncastle.com/\" target=\"_blank\">Conference call</a> to come tomorrow at 10:30 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17665172-crown-castle-reports-third-quarter-2019-results-provides-outlook-full-year-2020-announces-7\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3506350\" data-linked=\"Crown Castle +1.8% after Q3 beat\" data-tweet=\"$CCI - Crown Castle +1.8% after Q3 beat https://seekingalpha.com/news/3506350-crown-castleplus-1_8-after-q3-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3506350-crown-castleplus-1_8-after-q3-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506340\" data-ts=\"1571258896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AA\" target=\"_blank\">AA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506340-alcoa-reports-q3-loss-investors-like-portfolio-review-to-drive-lower-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcoa reports Q3 loss but investors like portfolio review to drive lower costs</a></h4><ul><li>Alcoa (NYSE:<a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a>) <font color=\"green\">+5.6%</font> after-hours despite reporting a larger than forecast <a href=\"https://seekingalpha.com/news/3506303-alcoa-eps-misses-0_15-misses-revenue\" target=\"_blank\">Q3 loss</a> and a 24% Y/Y revenue decline, as the company says it is launching a \"multi-year portfolio review aimed at driving lower costs and sustainable profitability with refined strategic priorities.\"</li><li>Over the next 12-18 months, Alcoa says it plans to pursue non-core asset sales expected to generate $500M-$1B in net proceeds, and over the next five years, the company says it will realign its operating portfolio and has placed under review 1.5M metric tons of smelting capacity and 4M metric tons of alumina refining capacity.</li><li>In Q3, Alcoa's adjusted EBITDA of $388M was $67M lower than the prior quarter, primarily due to lower alumina pricing that was partially offset by higher alumina sales volume and lower production costs.</li><li>For the full year, Alcoa continues to project a global aluminum deficit, in the range of 800K-1.2M metric tons, down slightly from the prior quarter's estimate of a 1M-1.4M mt deficit.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506340\" data-linked=\"Alcoa reports Q3 loss but investors like portfolio review to drive lower costs\" data-tweet=\"$AA - Alcoa reports Q3 loss but investors like portfolio review to drive lower costs https://seekingalpha.com/news/3506340-alcoa-reports-q3-loss-investors-like-portfolio-review-to-drive-lower-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3506340-alcoa-reports-q3-loss-investors-like-portfolio-review-to-drive-lower-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506338\" data-ts=\"1571258689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLNW\" target=\"_blank\">LLNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506338-limelight-networksplus-15-after-record-q3-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Limelight Networks +15% after record Q3 revenue</a></h4><ul>    <li>Limelight Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a>) is <font color=\"green\">up 15.2%</font> postmarket after topping revenue consensus with its <a href=\"https://seekingalpha.com/news/3506296-limelight-networks-eps-line-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li>    <li>Revenues rose 4% from the prior year and 12% sequentially, to a Q3-record $51.3M. It was also the company's second-highest revenue figure ever.</li>    <li>Net loss swelled on a GAAP basis to $2.8M from $0.3M; non-GAAP net income fell to $0.6M from $3.2M.</li>    <li>Adjusted EBITDA fell to $5.8M from a year-ago $7.7M.</li>    <li>\"We believe the fourth quarter will see year-over-year acceleration in revenue growth and meaningful improvements in gross margin and overall profitability,\" says CEO Bob Lento.</li>    <li>It's expecting 2019 revenue to end up at $200M-$210M, with non-GAAP EPS near break-even. Capital expenditures are forecast about $30M.</li>    <li><a href=\"https://seekingalpha.com/pr/17665079-limelight-networks-r-reports-financial-results-third-quarter-2019\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3506338\" data-linked=\"Limelight Networks +15% after record Q3 revenue\" data-tweet=\"$LLNW - Limelight Networks +15% after record Q3 revenue https://seekingalpha.com/news/3506338-limelight-networksplus-15-after-record-q3-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3506338-limelight-networksplus-15-after-record-q3-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506337\" data-ts=\"1571258275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URI\" target=\"_blank\">URI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506337-united-rentalsminus-3-after-narrowing-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Rentals -3% after narrowing outlook</a></h4><ul><li>United Rentals (NYSE:<a href='https://seekingalpha.com/symbol/URI' title='United Rentals, Inc.'>URI</a>) -3.3% <a href=\"https://seekingalpha.com/news/3506314-united-rentals-eps-beats-0_30-beats-revenue\" target=\"_blank\">reports</a> Q3 beats with 18% Y/Y revenue growth. The company narrows its FY19 outlook to revenue of $9.25-9.35B (was: $9.15-9.45B; consensus: $9.29B) and adjusted EBITDA of $4.35-4.4B (was: $4.35-4.5B).</li><li>Equipment rental revenue was $2.15B (consensus: $2.18B).</li><li>Fleet productivity was down 1.3% Y/Y actual and up 1.7% Y/Y pro forma.</li><li>Earnings call starts at 11 AM ET tomorrow with a webcast <a href=\"http://unitedrentals.com/\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17665156-united-rentals-announces-third-quarter-2019-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506337\" data-linked=\"United Rentals -3% after narrowing outlook\" data-tweet=\"$URI - United Rentals -3% after narrowing outlook https://seekingalpha.com/news/3506337-united-rentalsminus-3-after-narrowing-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3506337-united-rentalsminus-3-after-narrowing-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506324\" data-ts=\"1571257751\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506324-ibmminus-2_7-after-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM -2.7% after revenue miss</a></h4><ul><li>IBM (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) <font color=\"red\">-2.7%</font> <a href=\"https://seekingalpha.com/news/3506302-ibm-eps-beats-0_02-misses-revenue\" target=\"_blank\">reports</a> Q3 results that beat EPS estimates but missed on revenue with a 4% Y/Y decline. The company maintains its FY outlook with EPS of at least $12.80 and FCF of about $12B.</li><li>Revenue breakdown: Global Technology Services, $6.7B (consensus: $6.78B); Cloud and Cognitive Software, $5.28B (consensus: $5.41B); Global Business Services, $4.12B (consensus: $4.12B); Systems, $1.48B (consensus: $1.52B).</li><li>Red Hat revenue was up 19% Y/Y to $987M, normalized for historical comparability.</li><li>Cloud revenue totaled $5B in the quarter (+11%) and $20B over the past 12 months, compared to the 5% growth last quarter.</li><li>Net cash from operating activities amounted to $15.4B and FCF was $12.3B over the last 12 months.</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ibm.com%2Finvestor%2Fevents%2Fearnings%2F3q19.html&amp;esheet=52112576&amp;newsitemid=20191016005883&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.ibm.com%2Finvestor%2Fevents%2Fearnings%2F3q19.html&amp;index=1&amp;md5=c68734b4d4e1582b8f76a6c79bbc2f2f\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17665142-ibm-reports-2019-third-quarter-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506324\" data-linked=\"IBM -2.7% after revenue miss\" data-tweet=\"$IBM - IBM -2.7% after revenue miss https://seekingalpha.com/news/3506324-ibmminus-2_7-after-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3506324-ibmminus-2_7-after-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506320\" data-ts=\"1571257315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506320-netflixplus-10_7-profits-jump-amid-solid-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix +10.7% as profits jump amid solid growth</a></h4><ul>   <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is <font color=\"green\">up 10.7%</font> after hours in early reaction following <a href=\"https://seekingalpha.com/news/3506288-netflix-eps-beats-0_42-revenue-line\" target=\"_blank\">Q3 earnings</a> where profits topped expectations but subscriber growth fell a bit short of the company's guidance.</li>    <li>Revenues increased 31% to $5.25B, in line with consensus.</li>    <li>Operating income more than doubled year-over-year, to $980M, and operating margin increased to 18.7% from a year-ago 12%.</li>    <li>Meanwhile global streaming paid net adds were 6.77M, to end up at 158.33M (21.4% Y/Y gain). It had forecast gains of 7M subs.</li>    <li>\"As we\u2019ve improved the variety, diversity and quality of our content slate, member engagement has grown, revenue has increased, and we\u2019re able to further fund our content investment,\" it says.</li>    <li>In a note on competition (with several deep-pocketed rivals set to come on line): \"Many are focused on the 'streaming wars,' but we\u2019ve been competing with streamers (Amazon, YouTube, Hulu) as well as linear TV for over a decade.\" It's focused on the overall market opportunity, saying it believes it's less than 10% of TV screen time and much less on mobile.</li>    <li><a href=\"http://youtube.com/netflixir\" target=\"_blank\">Earnings interview</a> (with Guggenheim's Michael Morris) available at 6 p.m. ET.</li>    <li><a href=\"https://s22.q4cdn.com/959853165/files/doc_financials/quarterly_reports/2019/q3/FINAL-Q3-19-Shareholder-Letter.pdf\" target=\"_blank\">Investor letter</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3506320\" data-linked=\"Netflix +10.7% as profits jump amid solid growth\" data-tweet=\"$NFLX - Netflix +10.7% as profits jump amid solid growth https://seekingalpha.com/news/3506320-netflixplus-10_7-profits-jump-amid-solid-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3506320-netflixplus-10_7-profits-jump-amid-solid-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>98&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506313\" data-ts=\"1571257054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCI\" target=\"_blank\">CCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506313-crown-castle-ffo-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crown Castle FFO beats by $0.06, beats on revenue</a></h4><ul><li>Crown Castle (NYSE:<a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp. &#40;REIT&#41;'>CCI</a>): Q3 FFO of $1.49 <font color=\"green\">beats by $0.06</font>.</li><li>Revenue of $1.51B (+9.4% Y/Y) <font color=\"green\">beats by $30M</font>.</li><li>Shares <font color=\"green\">+1.2%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17665172-crown-castle-reports-third-quarter-2019-results-provides-outlook-full-year-2020-announces-7\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3506313\" data-linked=\"Crown Castle FFO beats by $0.06, beats on revenue\" data-tweet=\"$CCI - Crown Castle FFO beats by $0.06, beats on revenue https://seekingalpha.com/news/3506313-crown-castle-ffo-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3506313-crown-castle-ffo-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506308\" data-ts=\"1571256953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506308-csx-chugs-higher-on-q3-earnings-topper-operating-ratio-sets-record\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX chugs higher on Q3 earnings topper; operating ratio sets record</a></h4><ul><li>CSX Corp. (NASDAQ:<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a>) <font color=\"green\">+2.6%</font> after-hours following better than expected <a href=\"https://seekingalpha.com/news/3506290-csx-eps-beats-0_06-revenue-line\" target=\"_blank\">Q3 earnings</a>, highlighted by a new company record operating ratio of 56.8% vs. 58.7% in the prior-year quarter.</li><li>CSX says Q3 revenue fell 5% Y/Y to $2.98B, as merchandise revenue growth was more than offset by declines in the coal and intermodal units, but expenses decreased 8% to $1.69B, driven by continued efficiency gains and volume-related savings.</li><li>Q3 operating income came in roughly flat at $1.29B compared to the same period last year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506308\" data-linked=\"CSX chugs higher on Q3 earnings topper; operating ratio sets record\" data-tweet=\"$CSX - CSX chugs higher on Q3 earnings topper; operating ratio sets record https://seekingalpha.com/news/3506308-csx-chugs-higher-on-q3-earnings-topper-operating-ratio-sets-record?source=tweet\" data-url=\"https://seekingalpha.com/news/3506308-csx-chugs-higher-on-q3-earnings-topper-operating-ratio-sets-record\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506289\" data-ts=\"1571256234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOW\" target=\"_blank\">NOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506289-macquarie-calls-servicenow-concerns-overblown\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macquarie calls ServiceNow concerns &quot;overblown&quot;</a></h4><ul><li>Macquarie calls the ServiceNow (NYSE:<a href='https://seekingalpha.com/symbol/NOW' title='ServiceNow, Inc.'>NOW</a>) <font color=\"red\">-7%</font> pullback a buying opportunity as checks suggest a solid quarter and no pipeline slowdown.</li><li>The firm says some investors are concerned about potential leadership exits, but notes that NOW says its sales leads are committed to staying with the company.</li><li>Macquarie reiterates an Outperform rating and $335 price target. ServiceNow has an Outperform average <a href=\"https://seekingalpha.com/symbol/NOW/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Related: Earlier today, Morgan Stanley downgraded NOW to Equal-Weight due to near-term risks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506289\" data-linked=\"Macquarie calls ServiceNow concerns &quot;overblown&quot;\" data-tweet=\"$NOW - Macquarie calls ServiceNow concerns &quot;overblown&quot; https://seekingalpha.com/news/3506289-macquarie-calls-servicenow-concerns-overblown?source=tweet\" data-url=\"https://seekingalpha.com/news/3506289-macquarie-calls-servicenow-concerns-overblown\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506283\" data-ts=\"1571254791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CXO\" target=\"_blank\">CXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506283-concho-downgraded-diamondback-price-target-trimmed-suntrust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Concho downgraded, Diamondback price target trimmed at SunTrust</a></h4><ul><li>Concho Resources (<a href='https://seekingalpha.com/symbol/CXO' title='Concho Resources Inc.'>CXO</a> <font color='red'>-1.9%</font>) dips deeper into the red after SunTrust <a href=\"https://thefly.com/thestreet/realmoney/index.php/CXO;FANGid2975998/CXO;FANG-Concho-Resources-downgraded-to-Hold-from-Buy-at-SunTrust\" target=\"_blank\">downgrades shares to Hold</a> from Buy with a $70 price target, chopped from $100, as analyst Neal Dingmann thinks the company's production results will fall short of consensus even though the company already has reduced its 2019 oil growth forecast.</li><li>CXO has recently highlighted its efforts to remedy \"inflated well costs\" along with its plans to move to wider spaced projects, but Dingmann expects these actions will take time to flow through to the company's overall well profile.</li><li>Dingmann also lowers his price target on Diamondback Energy (<a href='https://seekingalpha.com/symbol/FANG' title='Diamondback Energy, Inc.'>FANG</a> <font color='red'>-1.2%</font>) to $125 from $145, forecasting more modest growth in Q3 production after a strong Q2, but maintains his Buy rating and predicts the company will raise its dividend to a \"more S&amp;P-500 competitive\" level.</li><li>CXO's average <a href=\"https://seekingalpha.com/symbol/CXO/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, while its <a href=\"https://seekingalpha.com/symbol/CXO/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506283\" data-linked=\"Concho downgraded, Diamondback price target trimmed at SunTrust\" data-tweet=\"$CXO $FANG - Concho downgraded, Diamondback price target trimmed at SunTrust https://seekingalpha.com/news/3506283-concho-downgraded-diamondback-price-target-trimmed-suntrust?source=tweet\" data-url=\"https://seekingalpha.com/news/3506283-concho-downgraded-diamondback-price-target-trimmed-suntrust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506282\" data-ts=\"1571254633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506282-cloud-stocks-slip-on-workday-worries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cloud stocks slip on Workday worries</a></h4><ul><li>Cloud software stocks are dropping after Workday's (NASDAQ:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday, Inc.'>WDAY</a>) analyst day event showed slowing growth for the company's Human Capital Management software.</li><li>Movers include Okta (<a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a> <font color='red'>-8.1%</font>), Splunk (<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a> <font color='red'>-5.6%</font>), and Atlassian (<a href='https://seekingalpha.com/symbol/TEAM' title='Atlassian Corporation Plc'>TEAM</a> <font color='red'>-4.1%</font>).</li><li>The iShares Expanded Tech-Software ETF (BATS:<a href='https://seekingalpha.com/symbol/IGV' title='iShares Expanded Tech-Software Sector ETF'>IGV</a>) is <font color=\"red\">down 2.4%</font> and the First Trust Cloud Computing ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/SKYY' title='First Trust Cloud Computing ETF'>SKYY</a>) is <font color=\"red\">down 1.9%</font> compared to the <font color=\"red\">0.8%</font> decline for the tech sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3506282\" data-linked=\"Cloud stocks slip on Workday worries\" data-tweet=\"$WDAY $OKTA $SPLK - Cloud stocks slip on Workday worries https://seekingalpha.com/news/3506282-cloud-stocks-slip-on-workday-worries?source=tweet\" data-url=\"https://seekingalpha.com/news/3506282-cloud-stocks-slip-on-workday-worries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506280\" data-ts=\"1571254299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLCE\" target=\"_blank\">PLCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506280-big-bounces-in-store-for-childrens-place-shoe-carnival-mox-reports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big bounces in store for Children&#39;s Place, Shoe Carnival - Mox Reports</a></h4><ul><li>A favorite trade of Mox Reports for the last few years has been buying the dip in oversold bricks and mortar retailers (\"BaMRs\" or \"Bammers\" as Mox likes to call them).</li><li>Along those lines, Mox has gone long Children's Place (<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place, Inc.'>PLCE</a> <font color='green'>+0.6%</font>) and Shoe Carnival (<a href='https://seekingalpha.com/symbol/SCVL' title='Shoe Carnival, Inc.'>SCVL</a> <font color='green'>+1.5%</font>), looking for a roughly 40%-60% move over the next 3-8 weeks.</li><li><a href=\"https://moxreports.com/long-plce-and-scvl-bammers/\" target=\"_blank\">Full report here</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3506280\" data-linked=\"Big bounces in store for Children&#39;s Place, Shoe Carnival - Mox Reports\" data-tweet=\"$PLCE $SCVL - Big bounces in store for Children&#39;s Place, Shoe Carnival - Mox Reports https://seekingalpha.com/news/3506280-big-bounces-in-store-for-childrens-place-shoe-carnival-mox-reports?source=tweet\" data-url=\"https://seekingalpha.com/news/3506280-big-bounces-in-store-for-childrens-place-shoe-carnival-mox-reports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506272\" data-ts=\"1571252367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506272-technology-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong>Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) <font color=\"green\">+26%</font>. SCWorx (NASDAQ:<a href='https://seekingalpha.com/symbol/WORX' title='SCWorx Corp.'>WORX</a>) <font color=\"green\">+14%</font>. Bridgeline Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/BLIN' title='Bridgeline Digital, Inc.'>BLIN</a>) <font color=\"green\">+9%</font>. JMU Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a>) <font color=\"green\">+8%</font>. Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) <font color=\"green\">+8%</font>.</li> <li><strong>Losers: </strong>Workday (NASDAQ:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday, Inc.'>WDAY</a>) <font color=\"red\">-12%</font>. Appian Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/APPN' title='Appian Corporation'>APPN</a>) <font color=\"red\">-10%</font>. Coupa Software Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Incorporated'>COUP</a>) <font color=\"red\">-10%</font>. Bel Fuse (NASDAQ:<a href='https://seekingalpha.com/symbol/BELFB' title='Bel Fuse Inc.'>BELFB</a>) <font color=\"red\">-10%</font>. Pareteum Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3506272\" data-linked=\"Technology - Top 5 Gainers / Losers\" data-tweet=\"$AEMD $WORX $BLIN - Technology - Top 5 Gainers / Losers https://seekingalpha.com/news/3506272-technology-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506272-technology-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506260\" data-ts=\"1571249145\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506260-ziopharm-down-11-on-bearish-sa-article\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm down 11% on bearish SA article</a></h4><ul><li>ZIOPHARM Oncology (<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a> <font color=\"red\">-10.8%</font>) is down on average volume in apparent response to a just-published <a href=\"https://seekingalpha.com/article/4296842-ziopharm-13-failed-programs-3-deck\" target=\"_blank\">article </a>on Seeking Alpha by Contributor Alpha Exposure who cites the company's sketchy product development track record, exemplified by the clinical hold on its autologous CAR T program.</li><li>Alpha sees 100% downside on the stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506260\" data-linked=\"Ziopharm down 11% on bearish SA article\" data-tweet=\"$ZIOP - Ziopharm down 11% on bearish SA article https://seekingalpha.com/news/3506260-ziopharm-down-11-on-bearish-sa-article?source=tweet\" data-url=\"https://seekingalpha.com/news/3506260-ziopharm-down-11-on-bearish-sa-article\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506262\" data-ts=\"1571249066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506262-mcdermott-and-ring-energy-among-energy-materials-gainers-westwater-resources-and-rayonier\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDermott and Ring Energy among Energy/Materials gainers; Westwater Resources and Rayonier Advanced Materials among losers</a></h4><ul><li><b>Gainers: </b>McDermott (NYSE:<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a>) <font color=\"green\">+10%</font>. Ring Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/REI' title='Ring Energy, Inc.'>REI</a>) <font color=\"green\">+9%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"green\">+8%</font>. Nabors Industries (NYSE:<a href='https://seekingalpha.com/symbol/NBR' title='Nabors Industries Ltd.'>NBR</a>) <font color=\"green\">+8%</font>. Auryn Resources (NYSEMKT:<a href='https://seekingalpha.com/symbol/AUG' title='Auryn Resources Inc.'>AUG</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Westwater Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/WWR' title='Westwater Resources, Inc.'>WWR</a>) <font color=\"red\">-18%</font>. Rayonier Advanced Materials (NYSE:<a href='https://seekingalpha.com/symbol/RYAM' title='Rayonier Advanced Materials Inc.'>RYAM</a>) <font color=\"red\">-10%</font>. TimkenSteel (NYSE:<a href='https://seekingalpha.com/symbol/TMST' title='TimkenSteel Corporation'>TMST</a>) <font color=\"red\">-8%</font>. Calumet Specialty Products Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a>) <font color=\"red\">-8%</font>. Olympic Steel (NASDAQ:<a href='https://seekingalpha.com/symbol/ZEUS' title='Olympic Steel, Inc.'>ZEUS</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506262\" data-linked=\"McDermott and Ring Energy among Energy/Materials gainers; Westwater Resources and Rayonier Advanced Materials among losers\" data-tweet=\"$MDR $REI $LEU - McDermott and Ring Energy among Energy/Materials gainers; Westwater Resources and Rayonier Advanced Materials among losers https://seekingalpha.com/news/3506262-mcdermott-and-ring-energy-among-energy-materials-gainers-westwater-resources-and-rayonier?source=tweet\" data-url=\"https://seekingalpha.com/news/3506262-mcdermott-and-ring-energy-among-energy-materials-gainers-westwater-resources-and-rayonier\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506245\" data-ts=\"1571245798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506245-loop-industries-leads-financial-gainers-jupai-holdings-and-vista-oil-gas-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loop Industries leads financial gainers; Jupai Holdings and Vista Oil &amp; Gas among losers</a></h4><ul><li><b>Gainers:</b> Loop Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LOOP' title='Loop Industries, Inc.'>LOOP</a>) <font color=\"green\">+7%</font>. Puyi (NASDAQ:<a href='https://seekingalpha.com/symbol/PUYI' title='Puyi Inc.'>PUYI</a>) <font color=\"green\">+6%</font>. Monroe Capital (NASDAQ:<a href='https://seekingalpha.com/symbol/MRCC' title='Monroe Capital'>MRCC</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Jupai Holdings (NYSE:<a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings Limited'>JP</a>) <font color=\"red\">-12%</font>. A-Mark Precious Metals (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRK' title='A-Mark Precious Metals, Inc.'>AMRK</a>) <font color=\"red\">-8%</font>. Vista Oil &amp; Gas (NYSE:<a href='https://seekingalpha.com/symbol/VIST' title='Vista Oil & Gas, S.A.B. de C.V.'>VIST</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506245\" data-linked=\"Loop Industries leads financial gainers; Jupai Holdings and Vista Oil &amp; Gas among losers\" data-tweet=\"$LOOP $PUYI $MRCC - Loop Industries leads financial gainers; Jupai Holdings and Vista Oil &amp; Gas among losers https://seekingalpha.com/news/3506245-loop-industries-leads-financial-gainers-jupai-holdings-and-vista-oil-gas-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506245-loop-industries-leads-financial-gainers-jupai-holdings-and-vista-oil-gas-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506243\" data-ts=\"1571245693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506243-new-age-beverages-flags-big-news-coming-from-nestea\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages flags &#39;big news&#39; coming from Nestea</a></h4><ul><li>New Age Beverages (<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color=\"green\">+21.5%</font>) explodes higher after the company tweets, \"<a href=\"https://twitter.com/NewAgeBevCo/status/1184504070205108224\" target=\"_blank\">Big news coming from #Nestea</a>.\"</li><li>Shares of Nestea-maker Coca-Cola (<a href='https://seekingalpha.com/symbol/KO' title='The Coca-Cola Company'>KO</a> <font color=\"red\">-0.3%</font>) show little reaction to the tweet.</li><li><strong>Update:</strong> In a <a href=\"https://twitter.com/NewAgeBevCo/status/1184547440524808192?s=20\" target=\"_blank\">new tweet</a>, NBEV announces the return of Nestea Instant Sweet Tea Mix.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506243\" data-linked=\"New Age Beverages flags &#39;big news&#39; coming from Nestea\" data-tweet=\"$NBEV $KO - New Age Beverages flags &#39;big news&#39; coming from Nestea https://seekingalpha.com/news/3506243-new-age-beverages-flags-big-news-coming-from-nestea?source=tweet\" data-url=\"https://seekingalpha.com/news/3506243-new-age-beverages-flags-big-news-coming-from-nestea\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506236\" data-ts=\"1571245351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506236-hovnanian-enterprises-and-cemtrex-among-industrial-gainers-avalon-holdings-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hovnanian Enterprises and Cemtrex among industrial gainers; Avalon Holdings among losers</a></h4><ul><li><b>Gainers: </b>Ideal Power (NASDAQ:<a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a>) <font color=\"green\">+34%</font>. Granite Construction (NYSE:<a href='https://seekingalpha.com/symbol/GVA' title='Granite Construction Incorporated'>GVA</a>) <font color=\"green\">+7%</font>. Hovnanian Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a>) <font color=\"green\">+6%</font>. Cemtrex (NASDAQ:<a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a>) <font color=\"green\">+6%</font>. Euro Tech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CLWT' title='Euro Tech Holdings Company Limited'>CLWT</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/BIMI' title='NF Energy Saving Corporation'>BIMI</a>) <font color=\"red\">-19%</font>. Avalon Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/AWX' title='Avalon Holdings Corporation'>AWX</a>) <font color=\"red\">-8%</font>. Pioneer Power Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/PPSI' title='Pioneer Power Solutions, Inc.'>PPSI</a>) <font color=\"red\">-6%</font>. Ryerson Holding (NYSE:<a href='https://seekingalpha.com/symbol/RYI' title='Ryerson Holding Corporation'>RYI</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506236\" data-linked=\"Hovnanian Enterprises and Cemtrex among industrial gainers; Avalon Holdings among losers\" data-tweet=\"$IPWR $GVA $HOV - Hovnanian Enterprises and Cemtrex among industrial gainers; Avalon Holdings among losers https://seekingalpha.com/news/3506236-hovnanian-enterprises-and-cemtrex-among-industrial-gainers-avalon-holdings-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506236-hovnanian-enterprises-and-cemtrex-among-industrial-gainers-avalon-holdings-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506234\" data-ts=\"1571244939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506234-wday-nbev-endp-and-achn-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WDAY, NBEV, ENDP and ACHN among midday movers</a></h4><ul><li><strong>Gainers: </strong>Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>) <font color=\"green\">+91%</font>. Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) <font color=\"green\">+71%</font>. Regional Health Properties (NYSEMKT:<a href='https://seekingalpha.com/symbol/RHE' title='Regional Health Properties, Inc.'>RHE</a>) <font color=\"green\">+53%</font>. Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"green\">+44%</font>. Assembly Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a>) <font color=\"green\">+30%</font>. Ideal Power (NASDAQ:<a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a>) <font color=\"green\">+29%</font>. Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) <font color=\"green\">+26%</font>. Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) <font color=\"green\">+24%</font>. New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+23%</font>. Enochian Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ENOB' title='Enochian Biosciences Inc.'>ENOB</a>) <font color=\"green\">+18%</font>.</li> <li><strong>Losers: </strong>Titan Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/TMDI' title='Titan Medical Inc.'>TMDI</a>) <font color=\"red\">-51%</font>. Synthesis Energy Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a>) <font color=\"red\">-21%</font>. Entera Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/ENTX' title='Entera Bio Ltd.'>ENTX</a>) <font color=\"red\">-19%</font>. Westwater Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/WWR' title='Westwater Resources, Inc.'>WWR</a>) <font color=\"red\">-19%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/BIMI' title='NF Energy Saving Corporation'>BIMI</a>) <font color=\"red\">-19%</font>. TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"red\">-18%</font>. American Vanguard (NYSE:<a href='https://seekingalpha.com/symbol/AVD' title='American Vanguard Corporation'>AVD</a>) <font color=\"red\">-13%</font>. Workday (NASDAQ:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday, Inc.'>WDAY</a>) <font color=\"red\">-13%</font>. Jupai Holdings (NYSE:<a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings Limited'>JP</a>) <font color=\"red\">-13%</font>. ViewRay (NASDAQ:<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay, Inc.'>VRAY</a>) <font color=\"red\">-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3506234\" data-linked=\"WDAY, NBEV, ENDP and ACHN among midday movers\" data-tweet=\"$VIVE $ACHN $RHE - WDAY, NBEV, ENDP and ACHN among midday movers https://seekingalpha.com/news/3506234-wday-nbev-endp-and-achn-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506234-wday-nbev-endp-and-achn-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506208\" data-ts=\"1571243497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XRT\" target=\"_blank\">XRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506208-retailers-outpace-broader-market-despite-disappointing-sales-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Retailers outpace broader market despite disappointing sales data</a></h4><ul><li>U.S. retail sales <a href=\"https://seekingalpha.com/news/3506086-retail-sales-disappoint\" target=\"_blank\">unexpectedly fell</a> last month, yet shares of a variety of retailers (<a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a> <font color='green'>+0.8%</font>) are outperforming the broader stock market today.</li><li>Even shares of automakers and auto-parts dealers - which reported the steepest decline in sales of the 13 major categories the Commerce Department tracks in its report - are largely higher for the day: <a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a> <font color=\"green\">+2.4%</font>, <a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color=\"green\">+1.8%</font>, <a href='https://seekingalpha.com/symbol/BWA' title='BorgWarner Inc.'>BWA</a> <font color=\"green\">+1.8%</font>, <a href='https://seekingalpha.com/symbol/ORLY' title='O&#39;Reilly Automotive, Inc.'>ORLY</a> <font color=\"green\">+1%</font>.</li><li><a href=\"https://www.wsj.com/articles/retail-stocks-shrug-off-weak-data-11571241141\" target=\"_blank\">One potential explanation</a> is that investors are not viewing one weak retail sales report as a sign that the U.S. consumer is set to suddenly cut down on spending in the coming months.</li><li>Despite uncertainty around trade policy, \"consumers still have a lot going for them as evidenced by longer-term trends and factors like the tight labor market,\" says Jack Kleinhenz, chief economist at the National Retail Federation.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLY' title='Consumer Discretionary Select Sector SPDR ETF'>XLY</a>, <a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>, <a href='https://seekingalpha.com/symbol/VCR' title='Vanguard Consumer Discretionary ETF'>VCR</a>, <a href='https://seekingalpha.com/symbol/FDIS' title='Fidelity Covington Trust - Fidelity MSCI Consumer Discretionary Index ETF'>FDIS</a>, <a href='https://seekingalpha.com/symbol/RTH' title='VanEck Vectors Retail ETF'>RTH</a>, <a href='https://seekingalpha.com/symbol/RETL' title='Direxion Daily Retail Bull 3x Shares ETF'>RETL</a>, <a href='https://seekingalpha.com/symbol/EMTY' title='ProShares Trust - ProShares Decline of the Retail Store ETF'>EMTY</a>, <a href='https://seekingalpha.com/symbol/IYC' title='iShares U.S. Consumer Services ETF'>IYC</a>, <a href='https://seekingalpha.com/symbol/IYK' title='iShares U.S. Consumer Goods ETF'>IYK</a>, <a href='https://seekingalpha.com/symbol/FXD' title='First Trust Consumer Discretionary AlphaDEX ETF'>FXD</a>, <a href='https://seekingalpha.com/symbol/UCC' title='ProShares Trust - ProShares Ultra Consumer Services'>UCC</a>, <a href='https://seekingalpha.com/symbol/RCD' title='Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight Consumer Discretionary ETF'>RCD</a>, <a href='https://seekingalpha.com/symbol/SCC' title='ProShares UltraShort Consumer Services ETF'>SCC</a>, <a href='https://seekingalpha.com/symbol/PMR' title='Invesco Exchange-Traded Fund Trust - Invesco Dynamic Retail ETF'>PMR</a>, <a href='https://seekingalpha.com/symbol/WANT' title='Direxion Daily Consumer Discretionary Bull 3X Shares'>WANT</a>, <a href='https://seekingalpha.com/symbol/UGE' title='ProShares Trust - ProShares Ultra Consumer Goods'>UGE</a>, <a href='https://seekingalpha.com/symbol/PASS' title='Direxion Daily Consumer Discretionary Bear 3X Shares'>PASS</a>, <a href='https://seekingalpha.com/symbol/SZK' title='ProShares Trust - ProShares UltraShort Consumer Goods'>SZK</a>, <a href='https://seekingalpha.com/symbol/FTXD' title='First Trust Exchange-Traded Fund VI - First Trust Nasdaq Retail ETF'>FTXD</a>, <a href='https://seekingalpha.com/symbol/JHMC' title='John Hancock Exchange-Traded Fund Trust - John Hancock Multifactor Consumer Discretionary ETF'>JHMC</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3506208\" data-linked=\"Retailers outpace broader market despite disappointing sales data\" data-tweet=\"$XRT $AAP $GM - Retailers outpace broader market despite disappointing sales data https://seekingalpha.com/news/3506208-retailers-outpace-broader-market-despite-disappointing-sales-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3506208-retailers-outpace-broader-market-despite-disappointing-sales-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506199\" data-ts=\"1571242904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSIC\" target=\"_blank\">HSIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506199-schein-up-2-on-dismissal-from-antitrust-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schein up 2% on dismissal from antitrust case</a></h4><ul><li>Dental products distributor Henry Schein (<a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a> <font color=\"green\">+1.5%</font>) is up on below-average volume in response to an <a href=\"https://www.ftc.gov/news-events/press-releases/2019/10/administrative-law-judge-partially-rules-favor-ftcs-complaint\" target=\"_blank\">initial decision</a> from an administrative law judge dropping the company from a Federal Trade Commission &#40;FTC&#41; antitrust complaint accusing it and fellow distributors Benco Dental Supply Company and Patterson Companies (<a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies, Inc.'>PDCO</a> <font color=\"green\">+0.9%</font>) of conspiring to refuse extending discounts to buying groups representing dentists.</li><li>Judge D. Michael Chappell held that Benco and Patterson were part of the conspiracy but Schein was not citing a lack of evidence to the contrary.</li><li>The three companies control over 85% of the U.S. market for sales of dental products and services.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506199\" data-linked=\"Schein up 2% on dismissal from antitrust case\" data-tweet=\"$HSIC $PDCO - Schein up 2% on dismissal from antitrust case https://seekingalpha.com/news/3506199-schein-up-2-on-dismissal-from-antitrust-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3506199-schein-up-2-on-dismissal-from-antitrust-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506198\" data-ts=\"1571242477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506198-starz-warns-of-drop-from-comcast-on-dec-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starz warns of drop from Comcast on Dec. 10</a></h4><ul>   <li>Cable network Starz (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a> <font color=\"red\">-1.7%</font>, <a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a> <font color=\"red\">-1.1%</font>) is warning customers on Comcast Xfinity (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color=\"red\">-0.1%</font>) that they'll <a href=\"https://seekingalpha.com/pr/17664852-starz-alerts-comcast-xfinity-customers-pending-loss-starz-channels\" target=\"_blank\">lose access to its 17 channels</a> as of Dec. 10.</li>    <li>Comcast notified its customers via website that it would replace Starz in its TV packages then, with Epix -- relegating the Starz networks to a tier with an additional $12/month charge.</li>    <li>The cableco had previously told Starz execs that it planned to drop its service by year-end.</li>    <li>\"We continue to try to reach an agreement with Comcast that is fair, reasonable and ensures our shared customers' continued access to a lineup of premium television content that speaks to them,\" Starz says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3506198\" data-linked=\"Starz warns of drop from Comcast on Dec. 10\" data-tweet=\"$LGF.A $LGF.B $CMCSA - Starz warns of drop from Comcast on Dec. 10 https://seekingalpha.com/news/3506198-starz-warns-of-drop-from-comcast-on-dec-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3506198-starz-warns-of-drop-from-comcast-on-dec-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506188\" data-ts=\"1571241882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506188-tenneco-leads-consumer-gainers-nio-and-tdh-holdings-in-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenneco leads consumer gainers; NIO and TDH Holdings in losers</a></h4><ul><li><b>Gainers: </b>Tenneco (NYSE:<a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a>) <font color=\"green\">+7%</font>. Workhorse Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a>) <font color=\"green\">+6%</font>. Planet Green Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp.'>PLAG</a>) <font color=\"green\">+5%</font>. Garrett Motion (NYSE:<a href='https://seekingalpha.com/symbol/GTX' title='Garrett Motion Inc.'>GTX</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"red\">-19%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Inc.'>NIO</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506188\" data-linked=\"Tenneco leads consumer gainers; NIO and TDH Holdings in losers\" data-tweet=\"$TEN $WKHS $PLAG - Tenneco leads consumer gainers; NIO and TDH Holdings in losers https://seekingalpha.com/news/3506188-tenneco-leads-consumer-gainers-nio-and-tdh-holdings-in-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506188-tenneco-leads-consumer-gainers-nio-and-tdh-holdings-in-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506186\" data-ts=\"1571241115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALLY\" target=\"_blank\">ALLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506186-ally-financialminus-3_5-analysts-pick-out-q3-weaknesses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ally Financial -3.5% as analysts pick out Q3 weaknesses</a></h4><ul><li>Ally Financial (NYSE:<a href='https://seekingalpha.com/symbol/ALLY' title='Ally Financial Inc.'>ALLY</a>) <font color=\"red\">falls 3.5%</font> after its Q3 beat included a couple of weak spots.</li><li>Credit costs edged higher with auto net charge-offs at 1.38% vs. 1.32%, up Y/Y for the first time since Q4 2017, writes Piper Jaffray analyst Kevin J. Barker; compares with 1.35% estimate.</li><li>\"Considering strength in used vehicle prices...we would have expected a better result,\" says Barker, who rates the stock at overweight with a $41 price target.</li><li>KBW analyst Sanjay Sakhrani notes some margin deceleration, such as in lower originated yields.</li><li>Seems to be a result of higher mix of retail customers and Y/Y rise in delinquency rates.</li><li>Rates at outperform with a price target of $39.</li><li>Quant rating is <a href=\"https://seekingalpha.com/symbol/ALLY/ratings/quant-ratings\" target=\"_blank\">Very Bullish</a>; SA Authors' average rating is <a href=\"https://seekingalpha.com/symbol/ALLY/ratings/author-ratings#filter=all\" target=\"_blank\">Neutral</a> (2 Bullish, 1 Bearish).</li><li><strong>Go deeper:</strong><a href=\"https://seekingalpha.com/symbol/ALLY/peers/comparison\" target=\"_blank\"> Compare Ally's key stats </a>with those of its peers.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3506075-ally-financial-plus-2_1-percent-q3-auto-originations-grow\" target=\"_blank\">Ally Financial +2.1% as Q3 auto originations grow</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3506186\" data-linked=\"Ally Financial -3.5% as analysts pick out Q3 weaknesses\" data-tweet=\"$ALLY - Ally Financial -3.5% as analysts pick out Q3 weaknesses https://seekingalpha.com/news/3506186-ally-financialminus-3_5-analysts-pick-out-q3-weaknesses?source=tweet\" data-url=\"https://seekingalpha.com/news/3506186-ally-financialminus-3_5-analysts-pick-out-q3-weaknesses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506141\" data-ts=\"1571240830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506141-boehringer-ingelheim-launches-mid-stage-study-of-new-cf-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boehringer Ingelheim launches mid-stage study of new CF treatment</a></h4><ul><li>Privately held Boehringer Ingelheim <a href=\"https://seekingalpha.com/pr/17664063-boehringer-ingelheim-announces-first-patient-enrolled-phase-ii-trial-novel-cystic-fibrosis\" target=\"_blank\">announces </a>the start of enrollment in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT04059094?lead=boehringer+ingelheim&amp;phase=1&amp;rank=2\" target=\"_blank\">Phase 2 clinical trial</a> evaluating different doses of BI 1265162, an epithelial sodium channel inhibitor delivered via the Respimat inhaler, in cystic fibrosis &#40;CF&#41; patients regardless of their mutation status.</li><li>The primary endpoint of the 98-subject study is the change from baseline in forced expiratory volume in one second (FEV1), a measure of lung function, up to four weeks. The estimated completion date is September 2020.</li><li>BI 12651621 is designed to keep the airways hydrated and less clogged with mucus via blocking the absorption of sodium. The company says the slow-moving mist delivered by Respimat helps patients inhale the medicine.</li><li>CF-related tickers: Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color=\"red\">-0.8%</font>), AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color=\"green\">+0.1%</font>), Proteostasis Therapeutics (<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a> <font color=\"green\">+1.2%</font>), Arrowhead Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals, Inc.'>ARWR</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3506141\" data-linked=\"Boehringer Ingelheim launches mid-stage study of new CF treatment\" data-tweet=\"$VRTX $ABBV $PTI - Boehringer Ingelheim launches mid-stage study of new CF treatment https://seekingalpha.com/news/3506141-boehringer-ingelheim-launches-mid-stage-study-of-new-cf-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3506141-boehringer-ingelheim-launches-mid-stage-study-of-new-cf-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506184\" data-ts=\"1571240672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506184-ionis-down-6-on-delay-of-huntingtons-disease-data-readout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis down 6% on delay of Huntington&#39;s disease data readout</a></h4><ul><li>Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color=\"red\">-5.8%</font>) slips on modestly higher volume in apparent reaction to collaboration Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a> <font color=\"red\">-1.2%</font>) disclosure that an expected data readout from their joint program, in this case a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03342053?cond=Huntington+Disease&amp;lead=roche&amp;rank=5\" target=\"_blank\">Phase 2 study</a> evaluating RO7234292 (ISIS 443139), in Huntington's disease will be delayed until late 2020 or early 2021. Previously, Roche indicated that additional data would be available in H1 2020.</li><li>The timeline for results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03761849?cond=Huntington+Disease&amp;lead=roche&amp;rank=4\" target=\"_blank\">Phase 3 trial</a> is still on track. If all goes well, marketing applications will be filed in 2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506184\" data-linked=\"Ionis down 6% on delay of Huntington&#39;s disease data readout\" data-tweet=\"$IONS $RHHBY - Ionis down 6% on delay of Huntington&#39;s disease data readout https://seekingalpha.com/news/3506184-ionis-down-6-on-delay-of-huntingtons-disease-data-readout?source=tweet\" data-url=\"https://seekingalpha.com/news/3506184-ionis-down-6-on-delay-of-huntingtons-disease-data-readout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506183\" data-ts=\"1571240385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506183-gm-uaw-reportedly-reach-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM/UAW reportedly reach deal</a></h4><ul><li>According to a UAW spokesperson, the union and General Motors (<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color=\"green\">+2.2%</font>) have come to a tentative agreement after a five week strike: <a href=\"https://uaw.org/uaw-national-negotiators-send-proposed-tentative-agreement-uaw-national-gm-council-approval/\" target=\"_blank\">UAW statement</a></li><li>Details of the proposed deal are not yet available, but the union's ~48K members with GM are <a href=\"https://www.cnbc.com/2019/10/16/gm-uaw-agree-on-tentative-labor-contract-that-could-end-strike.html\" target=\"_blank\">expected to receive  raises and bonuses</a>.</li><li>Based on previous proposals, GM also had said it would invest at least  $7B in its manufacturing operations and add thousands of new  hourly union jobs during the next four years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506183\" data-linked=\"GM/UAW reportedly reach deal\" data-tweet=\"$GM - GM/UAW reportedly reach deal https://seekingalpha.com/news/3506183-gm-uaw-reportedly-reach-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3506183-gm-uaw-reportedly-reach-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506181\" data-ts=\"1571239718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRRM\" target=\"_blank\">VRRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506181-verra-mobilityplus-1_5-on-european-tolling-acquisition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verra Mobility +1.5% on European tolling acquisition</a></h4><ul><li>Verra Mobility (NASDAQ:<a href='https://seekingalpha.com/symbol/VRRM' title='Verra Mobility Corporation'>VRRM</a>) <font color=\"green\">gains 1.5%</font> after agreeing<a href=\"https://seekingalpha.com/pr/17664626-verra-mobility-acquire-pagatelia-european-leader-facilitating-interoperable-tolling-four\" target=\"_blank\"> to acquire</a> Spanish company Pagatelia, a move that will bolster its tolling capabilities in southern Europe.</li><li>Pagatelia's platform manages electronic tolling transactions from more than 500,000 devices. Current customers include highway and parking operators, car manufacturers, financial institutions, and individual drivers.</li><li>\"The deal <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=bjeiek-b\" target=\"_blank\">dovetails nicely </a>with VRRM's acquisition last year of European Parking Collection, as well as the partnership with French tolling operator APPR that it announced last month,\" writes BTIG analyst Mark Palmer.</li><li>The transaction is expected to close at the end of October.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506181\" data-linked=\"Verra Mobility +1.5% on European tolling acquisition\" data-tweet=\"$VRRM - Verra Mobility +1.5% on European tolling acquisition https://seekingalpha.com/news/3506181-verra-mobilityplus-1_5-on-european-tolling-acquisition?source=tweet\" data-url=\"https://seekingalpha.com/news/3506181-verra-mobilityplus-1_5-on-european-tolling-acquisition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506166\" data-ts=\"1571238229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506166-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>) <font color=\"green\">+140%</font>. Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) <font color=\"green\">+69%</font>. Assembly Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a>) <font color=\"green\">+23%</font>. Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) <font color=\"green\">+23%</font>.  Regional Health Properties (NYSEMKT:<a href='https://seekingalpha.com/symbol/RHE' title='Regional Health Properties, Inc.'>RHE</a>) <font color=\"green\">+20%</font>.</li><li><b>Losers: </b>Titan Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/TMDI' title='Titan Medical Inc.'>TMDI</a>) <font color=\"red\">-47%</font>. Entera Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/ENTX' title='Entera Bio Ltd.'>ENTX</a>) <font color=\"red\">-19%</font>. ViewRay (NASDAQ:<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay, Inc.'>VRAY</a>) <font color=\"red\">-12%</font>. Natera (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRA' title='Natera, Inc.'>NTRA</a>) <font color=\"red\">-10%</font>. Rexahn Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REXN' title='Rexahn Pharmaceuticals, Inc.'>REXN</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506166\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$VIVE $ACHN $ASMB - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3506166-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506166-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506157\" data-ts=\"1571236298\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALRN\" target=\"_blank\">ALRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506157-early-stage-study-underway-on-ailerons-alrnminus-6924-myelopreservation-agent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Early-stage study underway on Aileron&#39;s ALRN-6924 as myelopreservation agent</a></h4><ul><li>The first participant has completed the initial cycle of treatment in a 120-subject <a href=\"https://clinicaltrials.gov/ct2/show/NCT04022876?intr=ALRN-6924&amp;lead=aileron&amp;phase=0&amp;rank=3\" target=\"_blank\">Phase 1b/2 clinical trial</a> evaluating Aileron Therapeutics' (<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics, Inc.'>ALRN</a> <font color=\"green\">+5.5%</font>) ALRN-6924 as a myelopreservation agent in patients with p52 mutation-positive small cell lung cancer &#40;SCLC&#41; treated with the chemo agent topotecan.</li><li>The objective of the first portion is safety and the determination of the recommended dose for the second portion. The primary endpoint of the second phase is the assessment of myelopreservation at month 12 as measured by the proportion of treated patients with serious/life-threatening/fatal neutropenia (abnormally low levels of white blood cells called neutrophils caused by certain chemo drugs, including topotecan).</li><li>The estimated primary completion date is March 2021.</li><li>ALRN-6924 is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt its interaction with <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161369/\" target=\"_blank\">MDMX and MDM2</a>, two proteins that interfere with its action. It is also in <a href=\"https://clinicaltrials.gov/ct2/show/NCT02264613?intr=ALRN-6924&amp;lead=aileron&amp;rank=2\" target=\"_blank\">development </a>for MDM2-amplified solid tumors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506157\" data-linked=\"Early-stage study underway on Aileron&#39;s ALRN-6924 as myelopreservation agent\" data-tweet=\"$ALRN - Early-stage study underway on Aileron&#39;s ALRN-6924 as myelopreservation agent https://seekingalpha.com/news/3506157-early-stage-study-underway-on-ailerons-alrnminus-6924-myelopreservation-agent?source=tweet\" data-url=\"https://seekingalpha.com/news/3506157-early-stage-study-underway-on-ailerons-alrnminus-6924-myelopreservation-agent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506149\" data-ts=\"1571234920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BYND\" target=\"_blank\">BYND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506149-hardees-to-test-market-beyond-meat-plant-based-options\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hardee&#39;s to test-market Beyond Meat plant-based options</a></h4><ul><li>Beyond Meat (<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a> <font color='green'>+3.2%</font>) sizzles in early trade after Hardee's restaurants said it would <a href=\"https://seekingalpha.com/pr/17664374-hardee-s-begin-testing-beyond-meat-breakfast-lunch-dinner-new-beyond-breakfast-sausage\" target=\"_blank\">offer plant-based meat options</a> in two test markets, Raleigh, N.C., and Kansas City, Mo.</li><li>Hardee's will test a new Beyond Breakfast Sausage Biscuit and an Original Beyond Thickburger for a limited time in the two markets, starting today.</li><li>Hardee's says it is kicking off the plant-based test in two markets with a strong college presence: \"We know college campuses specifically are helping to drive bold new conversations and lead culinary trends of the future, like the flexitarian diet,\" says the chain's senior director of brand marketing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506149\" data-linked=\"Hardee&#39;s to test-market Beyond Meat plant-based options\" data-tweet=\"$BYND - Hardee&#39;s to test-market Beyond Meat plant-based options https://seekingalpha.com/news/3506149-hardees-to-test-market-beyond-meat-plant-based-options?source=tweet\" data-url=\"https://seekingalpha.com/news/3506149-hardees-to-test-market-beyond-meat-plant-based-options\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506128\" data-ts=\"1571233137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMDI\" target=\"_blank\">TMDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506128-titan-medical-down-48-on-filing-amended-prospectus-and-withdrawing-milestones\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titan Medical down 48% on filing amended prospectus and withdrawing milestones</a></h4><ul> <li>Titan Medical (<a href='https://seekingalpha.com/symbol/TMDI' title='Titan Medical Inc.'>TMDI</a> <font color=\"red\">-47.7%</font>) has <a href=\"https://seekingalpha.com/pr/17663633-titan-medical-announces-filing-amended-restated-preliminary-prospectus-withdrawal-previously\" target=\"_blank\">filed</a> an amended and restated preliminary short form prospectus. Titan has also filed form F-10 under the U.S.-Canada Multijurisdictional Disclosure System.</li><li>Each of these filings is in connection with a proposed marketed offering of units, with each unit comprised of one common share and one common share purchase warrant of Company for total gross proceeds of a minimum of $15M and a maximum of $25M.</li>  <li>The Company is also withdrawing all milestones with respect to the development plan of its robotic surgical system.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3506128\" data-linked=\"Titan Medical down 48% on filing amended prospectus and withdrawing milestones\" data-tweet=\"$TMDI - Titan Medical down 48% on filing amended prospectus and withdrawing milestones https://seekingalpha.com/news/3506128-titan-medical-down-48-on-filing-amended-prospectus-and-withdrawing-milestones?source=tweet\" data-url=\"https://seekingalpha.com/news/3506128-titan-medical-down-48-on-filing-amended-prospectus-and-withdrawing-milestones\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506129\" data-ts=\"1571233132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTNP\" target=\"_blank\">TTNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506129-titan-pharma-down-51-after-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titan Pharma down 51% after pricing equity offering</a></h4><ul><li>Nano cap Titan Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a> <font color=\"red\">-51%</font>) slumps on an 8x surge in volume in early trade in reaction to its <a href=\"https://seekingalpha.com/pr/17664550-titan-pharmaceuticals-announces-pricing-9_0-million-underwritten-public-offering\" target=\"_blank\">public offering</a> of 40M Units at $0.225 per Unit.</li><li>Each Unit consists of one common share (or pre-funded warrant) and one five-year Class B Warrant to purchase one common share at $0.225.</li><li>Underwriters over-allotment is an additional 6M common shares and/or Class B Warrants to purchase up to 6M shares.</li><li>Closing date is October 18.</li><li>Yesterday's close was $0.370.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506129\" data-linked=\"Titan Pharma down 51% after pricing equity offering\" data-tweet=\"$TTNP - Titan Pharma down 51% after pricing equity offering https://seekingalpha.com/news/3506129-titan-pharma-down-51-after-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3506129-titan-pharma-down-51-after-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506120\" data-ts=\"1571232392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATOS\" target=\"_blank\">ATOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506120-atossa-up-10-premarket-on-irb-sign-off-of-mid-stage-study-of-microcatheter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atossa up 10% premarket on IRB sign-off of mid-stage study of microcatheter</a></h4><ul><li>Thinly traded nano cap Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) is up <font color=\"green\">10% </font>premarket on increased volume in reaction to its <a href=\"https://seekingalpha.com/pr/17664263-atossa-genetics-receives-irb-approval-phase-2-breast-cancer-study-using-intraductal\" target=\"_blank\">announcement </a>that the Institutional Review Board &#40;IRB&#41; has signed off on a Phase 2 clinical trial evaluating the company's intraductal microcatheter technology for the administration of fulvestrant (AstraZeneca's Faslodex) in patients with early-stage breast cancer or ductal carcinoma <em>in situ</em>.</li><li>Fulvestrant, approved in the U.S. for metastatic breast cancer, is currently administered via intramuscular injection, typically in the buttocks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506120\" data-linked=\"Atossa up 10% premarket on IRB sign-off of mid-stage study of microcatheter\" data-tweet=\"$ATOS - Atossa up 10% premarket on IRB sign-off of mid-stage study of microcatheter https://seekingalpha.com/news/3506120-atossa-up-10-premarket-on-irb-sign-off-of-mid-stage-study-of-microcatheter?source=tweet\" data-url=\"https://seekingalpha.com/news/3506120-atossa-up-10-premarket-on-irb-sign-off-of-mid-stage-study-of-microcatheter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506117\" data-ts=\"1571232142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGEN\" target=\"_blank\">MGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506117-miragen-up-25-premarket-on-positive-mrgminus-110-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiRagen up 25% premarket on positive MRG-110 data</a></h4><ul> <li>MiRagen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MGEN' title='Miragen Therapeutics, Inc.'>MGEN</a>) is up <font color=\"green\">25%</font> premarket after <a href=\"https://seekingalpha.com/pr/17663761-miragen-announces-new-clinical-data-showing-mrgminus-110-positively-impacted-tissue-repair\" target=\"_blank\">announcing</a> new data from two Phase 1 clinical trials of MRG-110, a microRNA-92 inhibitor.</li><li>The two Phase 1 studies investigated MRG-110 in excisional wounds.</li><li>Administration of MRG-110 was observed to increase angiogenesis, as demonstrated by increased perfusion and histological markers of neoangiogenesis, and</li><li>Reduce alpha-smooth muscle actin (α-SMA) expression, which has been show to correlate with activation of myofibroblasts.</li>        <li>In the intradermal multiple ascending dose study, the mean granulation tissue, or new connective tissue, area was decreased in subjects treated with MRG-110 when compared to placebo treated subjects\u2019 wounds.</li><li>In addition, MRG-110 was safe and generally well-tolerated when given as a single intravenous dose or as three weekly intradermal doses.</li>  <li>These new data will be included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society, held in Munich, Germany.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3506117\" data-linked=\"MiRagen up 25% premarket on positive MRG-110 data\" data-tweet=\"$MGEN - MiRagen up 25% premarket on positive MRG-110 data https://seekingalpha.com/news/3506117-miragen-up-25-premarket-on-positive-mrgminus-110-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3506117-miragen-up-25-premarket-on-positive-mrgminus-110-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506114\" data-ts=\"1571231827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRS\" target=\"_blank\">ACRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506114-aclaris-up-12-on-arkin-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aclaris up 12% on Arkin stake</a></h4><ul><li>Nano cap Aclaris Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics, Inc.'>ACRS</a>) is up <font color=\"green\">12%</font> premarket on modest volume in apparent reaction to a <a href=\"https://www.sec.gov/Archives/edgar/data/1321178/000092189519002554/sc13d00322acl_10072019.htm\" target=\"_blank\">13D filing</a> disclosing an 8% stake of ~3.3M common shares by institutional investor Arkin Holdings.</li><li>The company recently <a href=\"https://seekingalpha.com/news/3505130-aclaris-divests-rhofade-55m\" target=\"_blank\">sold the rights</a> to top seller Rhofade as it sharpens its focus on its immuno-inflammatory pipeline.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506114\" data-linked=\"Aclaris up 12% on Arkin stake\" data-tweet=\"$ACRS - Aclaris up 12% on Arkin stake https://seekingalpha.com/news/3506114-aclaris-up-12-on-arkin-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3506114-aclaris-up-12-on-arkin-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506113\" data-ts=\"1571231760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506113-mnk-mck-among-top-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MNK, MCK among top premarket gainers</a></h4><ul><li>Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>) <font color=\"green\">+109%</font> on <a href=\"https://seekingalpha.com/news/3506052-viveve-medical-92-percent-premarket\" target=\"_blank\">robust volume</a> on no particular news.</li><li>Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) <font color=\"green\">+75%</font> on <a href=\"https://seekingalpha.com/news/3506037-achillion-81-percent-930m-bid-alexion\" target=\"_blank\">$930M bid</a> from Alexion.</li><li>Ideal Power (NASDAQ:<a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a>) <font color=\"green\">+62%</font>.</li><li>Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"green\">+32%</font>.</li><li>Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/pr/17664263-atossa-genetics-receives-irb-approval-phase-2-breast-cancer-study-using-intraductal\" target=\"_blank\">receiving IRB approval</a> for phase 2 breast cancer study using intraductal technology.</li><li>Aclaris Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics, Inc.'>ACRS</a>) <font color=\"green\">+14%</font>.</li><li>Tech Data (NASDAQ:<a href='https://seekingalpha.com/symbol/TECD' title='Tech Data Corporation'>TECD</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/news/3505992-apollo-global-offers-5b-bid-tech-data-reuters\" target=\"_blank\">$5B bid</a> from Apollo Global.</li><li>Valeritas Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>) <font color=\"green\">+11%</font>.</li><li>CannTrust Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CTST' title='CannTrust Holdings Inc.'>CTST</a>) <font color=\"green\">+11%</font>.</li><li>Mallinckrodt plc (NYSE:<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt plc'>MNK</a>) <font color=\"green\">+7%</font> as <a href=\"https://seekingalpha.com/news/3506044-opioid-associated-players-improved-settlement-prospects\" target=\"_blank\">Opioid associated</a> players up on improved settlement prospects.</li><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"green\">+8%</font> as Los Angeles court <a href=\"https://seekingalpha.com/pr/17663715-los-angeles-court-rejects-patrick-soon-shiong-s-attempt-avoid-sorrento-litigation-allowing\" target=\"_blank\">rejects Patrick Soon-Shiong\u2019s attempt</a> to avoid litigation allowing arbitration case to move forward.</li><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3506092-axsome-completes-enrollment-late-stage-study-axsminus-05-mdd\" target=\"_blank\">completing enrollment</a> in late-stage study of AXS-05 in MDD.</li><li>Ocugen (NASDAQ:<a href='https://seekingalpha.com/symbol/OCGN' title='Ocugen, Inc.'>OCGN</a>) <font color=\"green\">+7%</font>.</li><li>McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>) <font color=\"green\">+6%</font> as <a href=\"https://seekingalpha.com/news/3505955-drug-wholesalers-perk-talks-settle-opioid-suits-18b\" target=\"_blank\">drug wholesalers perk up</a> on talks to settle opioid suits for $18B.</li><li>Sleep Number (NASDAQ:<a href='https://seekingalpha.com/symbol/SNBR' title='Sleep Number Corporation'>SNBR</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/news/3505910-sleep-number-eps-beats-0_15-beats-revenue\" target=\"_blank\">Q3 results</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506113\" data-linked=\"MNK, MCK among top premarket gainers\" data-tweet=\"$VIVE $ACHN $IPWR - MNK, MCK among top premarket gainers https://seekingalpha.com/news/3506113-mnk-mck-among-top-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506113-mnk-mck-among-top-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506112\" data-ts=\"1571231444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506112-prqr-tmdi-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PRQR, TMDI among premarket losers</a></h4><ul><li>Titan Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/TMDI' title='Titan Medical Inc.'>TMDI</a>) <font color=\"red\">-52%</font> on <a href=\"https://seekingalpha.com/pr/17663633-titan-medical-announces-filing-amended-restated-preliminary-prospectus-withdrawal-previously\" target=\"_blank\">filing</a> amended prospectus and withdrawing previous milestones.</li><li>Westwater Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/WWR' title='Westwater Resources, Inc.'>WWR</a>) <font color=\"red\">-17%</font>.</li><li>TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"red\">-17%</font>.</li><li>Synthesis Energy Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a>) <font color=\"red\">-14%</font>.</li><li>NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/BIMI' title='NF Energy Saving Corporation'>BIMI</a>) <font color=\"red\">-13%</font>.</li><li>ProQR Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics N.V.'>PRQR</a>) <font color=\"red\">-13%</font> on <a href=\"https://seekingalpha.com/news/3506004-proqr-prices-stock-offering-shares-12-percent-hours\" target=\"_blank\">pricing</a> stock offering.</li><li>Rhythm Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RYTM' title='Rhythm Pharmaceuticals, Inc.'>RYTM</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3506005-rhythm-pharmaceuticals-prices-stock-offering-shares-11-percent-hours\" target=\"_blank\">pricing</a> stock offering.</li><li>Workday (NASDAQ:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday, Inc.'>WDAY</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3506064-workday-cut-rising-event-shares-minus-5-percent\" target=\"_blank\">analyst</a> rating.</li><li>NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Inc.'>NIO</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3506112\" data-linked=\"PRQR, TMDI among premarket losers\" data-tweet=\"$TMDI $WWR $PETZ - PRQR, TMDI among premarket losers https://seekingalpha.com/news/3506112-prqr-tmdi-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3506112-prqr-tmdi-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506110\" data-ts=\"1571231170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYTU\" target=\"_blank\">AYTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506110-aytu-bio-up-11-premarket-ahead-of-natesto-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aytu Bio up 11% premarket ahead of Natesto data</a></h4><ul><li>Thinly traded nano cap Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) is up <font color=\"green\">11% </font>premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17664276-aytu-bioscience-announce-results-natesto-r-spermatogenesis-study-thursday-october-17\" target=\"_blank\">announcement </a>that it will release data tomorrow before the open from its Natesto Spermatogenesis Study.</li><li>The single-site trial evaluated Natesto (testosterone nasal gel) in hypogonadal men to restore clinically low serum testosterone levels aimed at maintaining sperm concentration, motility and total motile sperm count.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506110\" data-linked=\"Aytu Bio up 11% premarket ahead of Natesto data\" data-tweet=\"$AYTU - Aytu Bio up 11% premarket ahead of Natesto data https://seekingalpha.com/news/3506110-aytu-bio-up-11-premarket-ahead-of-natesto-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3506110-aytu-bio-up-11-premarket-ahead-of-natesto-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506102\" data-ts=\"1571230704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRMD\" target=\"_blank\">CRMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506102-cormedix-up-5-premarket-on-advancement-of-neutrolin-nda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CorMedix up 5% premarket on advancement of Neutrolin NDA</a></h4><ul><li>Thinly traded micro cap CorMedix (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix, Inc.'>CRMD</a>) is up <font color=\"green\">5%</font> premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17664218-cormedix-completes-successful-cmc-interaction-fda\" target=\"_blank\">announcement </a>that it has completed its interactions with the FDA regarding the Chemistry, Manufacturing and Controls &#40;CMC&#41; data package that will support its New Drug Application &#40;NDA&#41; for Neutrolin as a catheter lock solution for the prevention of catheter-related bloodstream infections in hemodialysis patients.</li><li>The company says the agency supports its proposed manufacturing program and plans to conduct a thorough review of the data package and commercial readiness of its manufacturing facilities at the time of filing.</li><li>A pre-NDA meeting has been scheduled.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506102\" data-linked=\"CorMedix up 5% premarket on advancement of Neutrolin NDA\" data-tweet=\"$CRMD - CorMedix up 5% premarket on advancement of Neutrolin NDA https://seekingalpha.com/news/3506102-cormedix-up-5-premarket-on-advancement-of-neutrolin-nda?source=tweet\" data-url=\"https://seekingalpha.com/news/3506102-cormedix-up-5-premarket-on-advancement-of-neutrolin-nda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506100\" data-ts=\"1571230179\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRON\" target=\"_blank\">CRON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506100-cronos-announces-jv-ipo-in-australia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cronos announces JV IPO in Australia</a></h4><ul><li>Cronos Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a>) <a href=\"https://seekingalpha.com/pr/17664261-cronos-group-issues-statement-separately-announced-ipo-cronos-australia\" target=\"_blank\">announces </a>the initial public offering of Cronos Australia Limited valued at A$20M via the issuance of 40M new shares at A$0.50 per share. Listing will commence next month.</li><li>Cronos Australia is a 50/50 joint venture with NewSouthern Capital Pty Ltd. After the debut, CRON will hold ~31% of the issued capital. Its initial market cap should be ~A$64.4M.</li><li>Shares up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506100\" data-linked=\"Cronos announces JV IPO in Australia\" data-tweet=\"$CRON - Cronos announces JV IPO in Australia https://seekingalpha.com/news/3506100-cronos-announces-jv-ipo-in-australia?source=tweet\" data-url=\"https://seekingalpha.com/news/3506100-cronos-announces-jv-ipo-in-australia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506097\" data-ts=\"1571229869\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOW\" target=\"_blank\">NOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506097-morgan-stanley-hits-now-sidelines-on-risks-nowminus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley hits NOW sidelines on risks; NOW -3%</a></h4><ul><li>Morgan Stanley downgrades ServiceNow (NYSE:<a href='https://seekingalpha.com/symbol/NOW' title='ServiceNow, Inc.'>NOW</a>) from Overweight to Equal-Weight with a $267 target.</li><li>Analyst Keith Weiss cites \"increasing near-term risks,\" which include \"a CFO transition, tough compares and high expectations.\"</li><li>Weiss says increased R&amp;D investments will weigh more materially on margin expansion.</li><li>Morgan Stanley still sees NOW as a \"best-in- class software asset.\"</li><li>NOW shares are <font color=\"red\">down 3.3% </font>pre-market to $265.33. The company has a Neutral <a href=\"https://seekingalpha.com/symbol/NOW/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506097\" data-linked=\"Morgan Stanley hits NOW sidelines on risks; NOW -3%\" data-tweet=\"$NOW - Morgan Stanley hits NOW sidelines on risks; NOW -3% https://seekingalpha.com/news/3506097-morgan-stanley-hits-now-sidelines-on-risks-nowminus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3506097-morgan-stanley-hits-now-sidelines-on-risks-nowminus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506095\" data-ts=\"1571229848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGR\" target=\"_blank\">PGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506095-progressive-eps-beats-0_12-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progressive EPS beats by $0.12, misses on revenue</a></h4><ul><li>Progressive (NYSE:<a href='https://seekingalpha.com/symbol/PGR' title='The Progressive Corporation'>PGR</a>): Q3 Non-GAAP EPS of $1.42 <font color=\"green\">beats by $0.12</font>; GAAP EPS of $1.42 <font color=\"green\">beats by $0.08</font>.</li><li>Revenue of $9.62B (+20.7% Y/Y) <font color=\"red\">misses by $40M</font>.</li><li>Shares <font color=\"green\">+1.4%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17664297-progressive-reports-september-2019-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3506095\" data-linked=\"Progressive EPS beats by $0.12, misses on revenue\" data-tweet=\"$PGR - Progressive EPS beats by $0.12, misses on revenue https://seekingalpha.com/news/3506095-progressive-eps-beats-0_12-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3506095-progressive-eps-beats-0_12-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506092\" data-ts=\"1571229404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506092-axsome-completes-enrollment-in-late-stage-study-of-axsminus-05-in-mdd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axsome completes enrollment in late-stage study of AXS-05 in MDD</a></h4><ul><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) has <a href=\"https://seekingalpha.com/pr/17663947-axsome-therapeutics-announces-completion-patient-enrollment-gemini-phase-3-trial-axsminus-05\" target=\"_blank\">completed enrollment</a> of ~300 subjects a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT04019704?lead=axsome+therapeutics&amp;phase=2&amp;rank=3\" target=\"_blank\">GEMINI</a>, evaluating AXS-05 (dextromethorphan/bupropion modulated delivery tablet) in patients with major depressive disorder &#40;MDD&#41;.</li><li>The primary efficacy endpoint is the change from baseline in an MDD scale called MADRS at week 6 versus placebo. Topline results should be available later this quarter.</li><li>AXS-05 is an NMDA receptor antagonist with multimodal activity.</li><li>Shares up <font color=\"green\">9%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506092\" data-linked=\"Axsome completes enrollment in late-stage study of AXS-05 in MDD\" data-tweet=\"$AXSM - Axsome completes enrollment in late-stage study of AXS-05 in MDD https://seekingalpha.com/news/3506092-axsome-completes-enrollment-in-late-stage-study-of-axsminus-05-in-mdd?source=tweet\" data-url=\"https://seekingalpha.com/news/3506092-axsome-completes-enrollment-in-late-stage-study-of-axsminus-05-in-mdd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506090\" data-ts=\"1571229363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTG\" target=\"_blank\">PSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506090-pure-storageplus-5-raymond-james-turns-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pure Storage +5% as Raymond James turns bullish</a></h4><ul><li>Raymond James upgrades Pure Storage (NYSE:<a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage, Inc.'>PSTG</a>) from Market Perform to Outperform with a $22 price target.</li><li>Analyst Simon Leopold cites checks suggesting PSTG sales have continued double-digit Y/Y growth and can outperform current estimates.</li><li>Pure Storage shares are <font color=\"green\">up 5.2%</font> pre-market to $18.56. The company has an Outperform average <a href=\"https://seekingalpha.com/symbol/PSTG/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506090\" data-linked=\"Pure Storage +5% as Raymond James turns bullish\" data-tweet=\"$PSTG - Pure Storage +5% as Raymond James turns bullish https://seekingalpha.com/news/3506090-pure-storageplus-5-raymond-james-turns-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3506090-pure-storageplus-5-raymond-james-turns-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506083\" data-ts=\"1571228621\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASMB\" target=\"_blank\">ASMB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506083-guggenheim-likes-axsome-therapeutics-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim likes Axsome Therapeutics in premarket analyst action</a></h4><ul><li>Assembly Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a>) initiated with Buy rating and $20 (115% upside) price target at Mizuho Securities.</li><li>Avid Bioservices (NASDAQ:<a href='https://seekingalpha.com/symbol/CDMO' title='Avid Bioservices, Inc.'>CDMO</a>) initiated with Buy rating and $11 (118% upside) price target at Craig-Hallum. Shares up <font color=\"green\">2% </font>premarket.</li><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) initiated with Buy rating and $48 (133% upside) price target at Guggenheim. Shares up <font color=\"green\">9% </font>premarket.</li><li>ChromaDex (NASDAQ:<a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Corporation'>CDXC</a>) initiated with Outperform rating and $6 price target at Oppenheimer.</li><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) upgraded to Neutral with a $129 (3% downside risk) price target at Atlantic Securities. Shares up <font color=\"green\">1% </font>premarket on improved prospects of a broad settlement of opioid epidemic-related litigation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506083\" data-linked=\"Guggenheim likes Axsome Therapeutics in premarket analyst action\" data-tweet=\"$ASMB $CDMO $AXSM - Guggenheim likes Axsome Therapeutics in premarket analyst action https://seekingalpha.com/news/3506083-guggenheim-likes-axsome-therapeutics-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3506083-guggenheim-likes-axsome-therapeutics-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506064\" data-ts=\"1571227145\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506064-workday-cut-after-rising-event-sharesminus-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday cut after Rising event; shares -5%</a></h4><ul><li>RBC maintains an Outperform rating on Workday (NASDAQ:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday, Inc.'>WDAY</a>) but cuts the target from $225 to $212, saying management \"presented a durable growth story, even as penetration into large accounts means a slowdown to the mid-20s is happening.\"</li><li>Macquarie Research (Neutral, $196 target) says that WDAY announced \"several new products that we think may be difficult to monetize.\"</li><li>Jefferies (Hold, $188) notes that the slowdown in HCM growth is offset by growth in Financials, but sees more attractive SaaS names that are growing at the same rate with better margin profiles and cheaper valuations.</li><li>Workday shares are <font color=\"red\">down 5%</font> pre-market to $171.96. The company has an Outperform average <a href=\"https://seekingalpha.com/symbol/WDAY/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506064\" data-linked=\"Workday cut after Rising event; shares -5%\" data-tweet=\"$WDAY - Workday cut after Rising event; shares -5% https://seekingalpha.com/news/3506064-workday-cut-after-rising-event-sharesminus-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3506064-workday-cut-after-rising-event-sharesminus-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506062\" data-ts=\"1571226895\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506062-abbott-down-2-premarket-after-trimming-eps-range\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abbott down 2% premarket after trimming EPS range</a></h4><ul><li>Abbott Laboratories (<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>) <a href=\"https://seekingalpha.com/pr/17664004-abbott-reports-third-quarter-2019-results\" target=\"_blank\">Q3 results</a>: Revenues: $8,076M (+5.5%); Nutrition: $1,874M (+2.0%); Diagnostics: $1,909M (+4.7%); Established Pharmaceuticals: $1,212M (+4.4%); Medical Devices: $3,065M (+8.9%).</li><li>Net Income: $960M (+73.9%); EPS: $0.53 (+71.0%); Non-GAAP Net Income: $1,514M (+12.8%); Non-GAAP EPS: $0.84 (+12.0%).</li><li><strong>2019 Guidance</strong>: GAAP EPS: $2.06 - 2.08 from $2.06 - 2.12; Non-GAAP EPS: $3.23 - 3.25 from $3.21 - 3.27.</li><li><strong>Q4 Guidance</strong>: GAAP EPS: $0.59 - 0.61; Non-GAAP EPS: $0.94 - 0.96.</li><li>Shares are down <font color=\"red\">2%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3506054-abbott-laboratories-eps-revenue-line\" target=\"_blank\">Abbott Laboratories EPS and revenue in-line</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3506062\" data-linked=\"Abbott down 2% premarket after trimming EPS range\" data-tweet=\"$ABT - Abbott down 2% premarket after trimming EPS range https://seekingalpha.com/news/3506062-abbott-down-2-premarket-after-trimming-eps-range?source=tweet\" data-url=\"https://seekingalpha.com/news/3506062-abbott-down-2-premarket-after-trimming-eps-range\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506063\" data-ts=\"1571226695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WORK\" target=\"_blank\">WORK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506063-slackminus-1_5-on-morgan-stanley-trim\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Slack -1.5% on Morgan Stanley trim</a></h4><ul><li>Morgan Stanley drops its Slack (NYSE:<a href='https://seekingalpha.com/symbol/WORK' title='Slack Technologies, Inc.'>WORK</a>) target by $10 to $28 while maintaining an Equal-Weight rating.</li><li>Analyst Keith Weiss still sees long-term opportunity, but doesn't think Slack stands to gain from expanding multiples. Weiss says upside from current levels would require \"more gradual outperformance over time.\"</li><li>Weiss also cites competition from Microsoft's Teams, which will limit Slack's realizable TAM.</li><li>Slack shares are <font color=\"red\">down 1.5%</font> pre-market to $24.37. The company has a Neutral average <a href=\"https://seekingalpha.com/symbol/WORK/ratings/author-ratings#filter=all\" target=\"_blank\">SA Authors' rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506063\" data-linked=\"Slack -1.5% on Morgan Stanley trim\" data-tweet=\"$WORK - Slack -1.5% on Morgan Stanley trim https://seekingalpha.com/news/3506063-slackminus-1_5-on-morgan-stanley-trim?source=tweet\" data-url=\"https://seekingalpha.com/news/3506063-slackminus-1_5-on-morgan-stanley-trim\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506059\" data-ts=\"1571226322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506059-adobeminus-2_7-citi-hits-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe -2.7% as Citi hits sidelines</a></h4><ul><li>Citi cuts Adobe (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Inc.'>ADBE</a>) from Buy to Neutral and lowers the price target from $322 to $313.</li><li>The firm cites concerns about Adobe's \"ability to continue the financial momentum it has had over the last 5+ years,\" seeing growth expectations for the Digital Experience business as \"too high based on current trends.\"</li><li>Upcoming catalyst: The analyst day in November, which Citi expects to include a FY20 outlook that's less conservative than past forecasts.</li><li>Adobe shares are <font color=\"red\">down 2.7% </font>pre-market to $271.99. The company has an Outperform average <a href=\"https://seekingalpha.com/symbol/ADBE/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506059\" data-linked=\"Adobe -2.7% as Citi hits sidelines\" data-tweet=\"$ADBE - Adobe -2.7% as Citi hits sidelines https://seekingalpha.com/news/3506059-adobeminus-2_7-citi-hits-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3506059-adobeminus-2_7-citi-hits-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506052\" data-ts=\"1571225428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVE\" target=\"_blank\">VIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506052-viveve-medical-up-92-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viveve Medical up 92% premarket</a></h4><ul><li>Thinly traded nano cap Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>) is up <font color=\"green\">92% </font>premarket on robust volume on no particular news.</li><li>Last week, it filed a <a href=\"https://seekingalpha.com/news/3505205-viveve-medical-17-percent-premarket-planned-equity-offering\" target=\"_blank\">prospectus </a>for a public offering of Class A &amp; B Units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506052\" data-linked=\"Viveve Medical up 92% premarket\" data-tweet=\"$VIVE - Viveve Medical up 92% premarket https://seekingalpha.com/news/3506052-viveve-medical-up-92-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3506052-viveve-medical-up-92-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506044\" data-ts=\"1571223773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506044-opioid-associated-players-up-on-improved-settlement-prospects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opioid associated players up on improved settlement prospects</a></h4><ul><li>The spike in buying in drug distributors yesterday after the close in reaction to the news that they are closing in on a <a href=\"https://seekingalpha.com/news/3505955-drug-wholesalers-perk-talks-settle-opioid-suits-18b\" target=\"_blank\">broad settlement</a> with states and local governments over their role in the opioid epidemic has other companies with potential legal exposure in the green premarket.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) (<font color=\"green\">+5%</font>), Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) (<font color=\"green\">+3%</font>), Mallinckrodt (NYSE:<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt plc'>MNK</a>) (<font color=\"green\">+8%</font>), Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) (<font color=\"green\">+1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3506044\" data-linked=\"Opioid associated players up on improved settlement prospects\" data-tweet=\"$TEVA $ENDP $MNK - Opioid associated players up on improved settlement prospects https://seekingalpha.com/news/3506044-opioid-associated-players-up-on-improved-settlement-prospects?source=tweet\" data-url=\"https://seekingalpha.com/news/3506044-opioid-associated-players-up-on-improved-settlement-prospects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506041\" data-ts=\"1571223249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BK\" target=\"_blank\">BK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506041-bank-of-new-york-q3-challenged-year-ago-aum-outflows\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of New York Q3 challenged by year-ago AUM outflows</a></h4><ul><li>Bank of New York Mellon (NYSE:<a href='https://seekingalpha.com/symbol/BK' title='The Bank of New York Mellon Corporation'>BK</a>)<a href=\"https://seekingalpha.com/pr/17663878-bny-mellon-reports-third-quarter-2019-earnings-1_0-billion-1_07-per-common-share\" target=\"_blank\"> Q3 EPS</a> of $1.07 exceeds the average analyst estimate of 99 cents and rises from $1.01 in Q2 and $1.06 in the year-ago quarter.</li><li>BK <font color=\"green\">jumps 2.3%</font> in premarket trading.</li><li>Q3 net interest revenue of $730M falls 9% Q/Q and 18% Y/Y, driven by lease-related impairment of $70M, or 6 cents per share; net interest margin on FTE basis of 1.00% compares with 1.12% in Q2 and 1.28% in Q3 2018.</li><li>Q3 fee revenue of $3.13B rises 1% Q/Q and falls 1% Y/Y; Y/Y decline reflects cumulative assets under management outflows since Q3 2018, lower performance fees and the unfavorable impact of a stronger U.S. dollar, partly offset by higher fees in Issuer Services and Clearance and Collateral Management and higher client assets and volumes in Pershing.</li><li>Assets under custody/administration of $35.8T rises 4% Y/Y primarily on higher market values and net new business, partly offset by the unfavorable impact of a stronger U.S. dollar.</li><li>AUM of $1.9T rose 3% Y/Y on higher market values, partly offset by the stronger U.S. dollar and net outflows.</li><li><a href=\"http://www.bnymellon.com/investorrelations\" target=\"_blank\">Conference call</a> at 8:00 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3506030-bank-new-york-mellon-eps-beats-0_08-misses-revenue\" target=\"_blank\">Bank of New York Mellon EPS beats by $0.08, misses on revenue</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3506041\" data-linked=\"Bank of New York Q3 challenged by year-ago AUM outflows\" data-tweet=\"$BK - Bank of New York Q3 challenged by year-ago AUM outflows https://seekingalpha.com/news/3506041-bank-of-new-york-q3-challenged-year-ago-aum-outflows?source=tweet\" data-url=\"https://seekingalpha.com/news/3506041-bank-of-new-york-q3-challenged-year-ago-aum-outflows\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506040\" data-ts=\"1571223158\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USB\" target=\"_blank\">USB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506040-u-s-bancorp-eps-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Bancorp EPS beats by $0.04, beats on revenue</a></h4><ul><li>U.S. Bancorp (NYSE:<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a>): Q3 GAAP EPS of $1.15 <font color=\"green\">beats by $0.04</font>.</li><li>Revenue of $5.92B (+3.9% Y/Y) <font color=\"green\">beats by $110M</font>.</li><li>Shares <font color=\"green\">+1.5%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17663883-u-s-bancorp-reports-third-quarter-2019-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3506040\" data-linked=\"U.S. Bancorp EPS beats by $0.04, beats on revenue\" data-tweet=\"$USB - U.S. Bancorp EPS beats by $0.04, beats on revenue https://seekingalpha.com/news/3506040-u-s-bancorp-eps-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3506040-u-s-bancorp-eps-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506038\" data-ts=\"1571223098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506038-bank-of-america-eps-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of America EPS beats by $0.07, beats on revenue</a></h4><ul><li>Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>): Q3 Non-GAAP EPS of $0.75 <font color=\"green\">beats by $0.07</font>; GAAP EPS of $0.56 <font color=\"green\">beats by $0.05</font>.</li><li>Revenue of $22.8B (+0.4% Y/Y) <font color=\"green\">beats by $70M</font>.</li><li>Shares <font color=\"green\">+1.2%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17663890-bank-america-reports-third-quarter-2019-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3506038\" data-linked=\"Bank of America EPS beats by $0.07, beats on revenue\" data-tweet=\"$BAC - Bank of America EPS beats by $0.07, beats on revenue https://seekingalpha.com/news/3506038-bank-of-america-eps-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3506038-bank-of-america-eps-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3506037\" data-ts=\"1571222985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3506037-achillion-up-81-on-930m-bid-from-alexion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achillion up 81% on $930M bid from Alexion</a></h4><ul><li>Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>) has <a href=\"https://seekingalpha.com/pr/17663861-alexion-acquire-achillion\" target=\"_blank\">agreed to acquire</a> Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) for $6.30 per share in cash for a total of ~$930M, including Achillion's cash on hand of ~$230M.</li><li>The deal includes non-tradeable contingent value rights (CVRs) that will pay Achillion shareholders $1.00 per share if danicopan is approved in the U.S. and $1.00 per share upon the start of Phase 3 development of complement factor D inhibitor ACH-5228.</li><li>The transaction should close in H1 2020.</li><li>ACHN, which closed at $3.65 yesterday, is up <font color=\"green\">81%</font> premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3506037\" data-linked=\"Achillion up 81% on $930M bid from Alexion\" data-tweet=\"$ALXN $ACHN - Achillion up 81% on $930M bid from Alexion https://seekingalpha.com/news/3506037-achillion-up-81-on-930m-bid-from-alexion?source=tweet\" data-url=\"https://seekingalpha.com/news/3506037-achillion-up-81-on-930m-bid-from-alexion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":61,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}